文献速递浆细胞疾病

泊马度胺联合环磷酰胺和地塞米松治疗老年复发难治多发性骨髓瘤:韩国多发性骨髓瘤工作组KMMWP-164研究

Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
PubMed 文献 · Am J Hematol · 2020-01-24

这项2期临床试验纳入55例老年复发难治多发性骨髓瘤患者,评估泊马度胺、环磷酰胺和地塞米松(PCd)方案的疗效与安全性。总缓解率为58.2%,临床获益率为72.7%,中位无进展生存期6.90个月,中位总生存期18.48个月。≥3级非血液学毒性发生率为70.8%,感染是主要致病和致死原因。

要点

  • PCd方案在老年复发难治骨髓瘤中ORR达58.2%,CBR达72.7%。
  • 中位PFS为6.90个月,中位OS为18.48个月。
  • ≥3级非血液学毒性发生率高(70.8%),感染需重点防范。

核心结论

  • PCd方案对硼替佐米和来那度胺均治疗失败的老年复发难治多发性骨髓瘤患者有效,但治疗相关感染是主要致病和致死原因。

研究设计与样本

  • 2期临床试验,纳入55例老年复发难治多发性骨髓瘤患者,接受28天周期的PCd方案治疗。

主要发现

  • 总缓解率为58.2%,临床获益率为72.7%。
  • 中位无进展生存期为6.90个月(95%CI 4.7-9.0),中位总生存期为18.48个月(95%CI 9.4-27.6)。
  • ≥3级非血液学毒性发生率为70.8%,原发性感染发生率为45.4%,其中肺炎21.8%、脓毒症9.0%、发热性中性粒细胞减少14.6%。

关键数值与推荐

  • 患者中位年龄73.3岁(范围64-86),≥80岁者占14.5%。
  • III期(修订国际分期系统)占14.5%,衰弱状态(简化衰弱量表)占56.4%。
  • 给药方案:泊马度胺4 mg/日口服,第1-21天;环磷酰胺400 mg/日口服,第1、8、15天;联合地塞米松。

临床怎么用

  • 对于硼替佐米和来那度胺均失败的老年复发难治多发性骨髓瘤患者,PCd方案是可考虑的有效选择。
  • 治疗期间需密切监测和预防感染,因感染发生率高且为主要致病和致死原因。

局限性

  • 本研究为单臂2期临床试验,样本量较小(55例),结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with transplant-ineligible relapsed and refractory multiple myeloma (RRMM) have a short life expectancy, especially when they have failed both the proteasome inhibitor and immunomodulator therapies. This study aimed to assess the efficacy and safety of pomalidomide, cyclophosphamide, and dexamethasone (PCd) in elderly patients with RRMM. This phase 2 clinical trial recruited 55 elderly patients with RRMM. The patients underwent a 28-day treatment cycle: pomalidomide (4 mg/day on days 1-21, administered orally) and cyclophosphamide (400 mg/day on days 1, 8, and 15; administered orally) plus dexamethasone. The median (range) age of the patients was 73.3 (64-86) years, and 8 (14.5%) patients who were ≥ 80 years old. Eight (14.5%) and 31 (56.4%) patients exhibited stage III (revised international staging system) and frail status (simplified frailty scale), respectively. The overall response rate (ORR) and clinical benefit rate (CBR) of PCd therapy were 58.2% and 72.7%, respectively. The median PFS and median overall survival (OS) were 6.90 months (95% CI, 4.7-9.0) and 18.48 months (95% CI, 9.4-27.6), respectively. The incidence rate of grade ≥ 3 non-hematological toxicities was 70.8%. In particular, the incidence rate of primary infection was 45.4%, including 21.8% for pneumonia, 9.0% for sepsis, and 14.6% for febrile neutropenia. In conclusion, PCd is an effective regimen for elderly patients with RRMM who had failed both bortezomib and lenalidomide treatments, but in whom the treatment-associated infection is the main cause of morbidity and mortality.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Lee HS, Kim K, Kim SJ, et al. Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study). Am J Hematol. 2020. PMID: 31919872. doi:10.1002/ajh.25726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。